

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of inhibitors of the interaction between HIV-1 TAT protein and HIV-1 gp 120 for inhibiting the entry of HIV-1 into a host cell.
2. (Original) Use of claim 1, wherein the inhibitor binds to TAT.
3. (Original) Use of claim 2, wherein the inhibitor is a peptide.
4. (Original) Use of claim 3, wherein the peptide is homologous to the gp 120 V1/V2 region.
5. (Currently Amended) Use of claim 3 ~~or~~ 4, wherein the peptide is selected from:
 - (a) CTVECYFNCTPTC (SEQ ID No. 2)
 - (b) CPDRKKKVVMVC (SEQ ID No. 3)
 - (c) CSFNITTEIRDKVKK (SEQ ID No. 127)
 - (d) a peptide comprising at least 5 contiguous amino acids from a peptide, selected from the group consisting of peptides (a) - (c),
 - (e) a peptide which has a sequence identity of at least 80 % to the amino acid sequence of a peptide selected from the group consisting of peptides (a) - (d).
6. (Currently Amended) Use of claim 3 ~~or~~ 4, wherein the peptide is selected from:
 - (a) RDKKKK (SEQ ID No. 40),
 - (b) RDKKKQ (SEQ ID No. 41),
 - (c) RDKKKV (SEQ ID No. 42),
 - (d) RNKRKQ (SEQ ID No. 51),
 - (e) RDKTQK (SEQ ID No. 52),
 - (f) DRKKKV (SEQ ID No. 43),
 - (g) KDKKEK (SEQ ID No. 45),

- (h) RDKQQK (SEQ ID No. 49),
 - (i) RDKVQK (SEQ ID No. 50),
 - (j) CSFNIT (SEQ ID No. 4),
 - (k) RDKVKK (SEQ ID No. 44),
 - (l) a peptide comprising at least 5 contiguous amino acids from a peptide selected from the group consisting of peptides (a) -(k),
 - (m) a peptide which has an identity of at least 80 % to the amino acid sequence of peptide selected from the group consisting of peptides (a) - (l).
7. (Original) Use of claim 1, wherein the inhibitor binds to gp120.
 8. (Currently Amended) Use of ~~any one of claims 1 to 7~~ Claim 1, wherein the host cell is a human cell.
 9. (Currently Amended) Use of ~~any one of claims 1 to 8~~ Claim 1 for the manufacture of a medicament for the treatment of HIV-1 infections.
 10. (Original) Use of claim 9 for the treatment of infections by M-tropic and L-tropic HIV-1 strains.
 11. (Original) A method for identifying and/or characterizing a compound which inhibits the entry of HIV-1 into a host cell comprising
 - (i) providing at least one compound to be tested and
 - (ii) determining if the compound is capable of inhibiting the interaction between HIV-1 TAT protein and HIV-1 gp120.
 12. (Original) The method of claim 11, wherein a plurality of compounds is tested in parallel or sequential.
 13. (Original) The method of claim 12, wherein a compound library is tested.

14. (Currently Amended) The method of ~~any one of claims 11 to 13~~ Claim 11, which is a cellular-based assay.
15. (Currently Amended) The method of ~~any one of claims 11 to 14~~ Claim 11, which is a molecular-based assay.
16. (Currently Amended) The method of ~~any one of claims 11 to 15~~ Claim 11, wherein a compound which has been identified as an inhibitor or a compound desired therefrom is formulated as a pharmaceutical composition.
17. (Original) A pharmaceutical composition comprising as an active ingredient at least one inhibitor of the interaction between HIV-1 TAT protein and HIV-1 gp 120 and optionally pharmaceutically acceptable carriers, diluents and/or adjuvants.
18. (Currently Amended) The pharmaceutical composition of claim 17, wherein the inhibitor is ~~defined as in claims 2 to 7~~ binds to TAT.
19. (Original) A peptide which is selected from:
 - (a) CTVECYFNCTPTC (SEQ ID No. 2)
 - (b) CPDRKKKVVMVC (SEQ ID No. 3)
 - (c) CSFNITTEIRDKVKK (SEQ ID No. 127)
 - (d) a peptide comprising at least 5 contiguous amino acids from a peptide, selected from the group consisting of peptides (a) - (c),
 - (e) a peptide which has a sequence identity of at least 80 % to the amino acid sequence of a peptide selected from the group consisting of peptides (a) - (d).
20. (Original) A peptide which is selected from:
 - (a) RDKKKK (SEQ ID No. 40),
 - (b) RDKKKQ (SEQ ID No. 41),
 - (c) RDKKKV (SEQ ID No. 42),
 - (d) RNKRKQ (SEQ ID No. 51),

- (e) RDKTQK (SEQ ID No. 52),
 - (f) DRKKKV (SEQ ID No. 43),
 - (g) KDKKEK (SEQ ID No. 45),
 - (h) RDKQQK (SEQ ID No. 49),
 - (i) RDKVQK (SEQ ID No. 50),
 - (j) CSFNIT (SEQ ID No. 4),
 - (k) RDKVKK (SEQ ID No. 44),
 - (l) a peptide comprising at least 5 contiguous amino acids from a peptide selected from the group consisting of peptides (a) -(k),
 - (m) a peptide which has an identity of at least 80 % to the amino acid sequence of peptide selected from the group consisting of peptides (a) - (l).
21. (Original) Peptide combination comprising at least two peptides with the sequences shown in SEQ ID NO. 2-127.
22. (Original) Peptide combination of claim 21, wherein at least one disulfide bridge is present.